Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Ожирение и артериальная гипертензия. Часть I: снижение веса и нормализация артериального давления

Полный текст:

Аннотация

Обзор посвящен проблеме артериальной гипертензии (АГ) на фоне ожирения. Особое внимание уделяется методам немедикаментозной и медикаментозной коррекции веса и их влиянию на уровень артериального давления (АД). Проведен анализ безопасности применения сибутрамина при сочетании АГ и ожирения. Приведены данные о наиболее эффективных режимах антигипертензивной терапии на фоне применения медикаментозных средств для снижения веса.

Об авторах

С. В. Недогода
Волгоградский государственный медицинский университет. Волгоград
Россия


И. Н. Барыкина
Волгоградский государственный медицинский университет. Волгоград
Россия


У. А. Брель
Волгоградский государственный медицинский университет. Волгоград
Россия


Л. В. Бутрина
Волгоградский государственный медицинский университет. Волгоград
Россия


Т. А. Чаляби
Волгоградский государственный медицинский университет. Волгоград
Россия


Список литературы

1. A randomised trial of sibutramine in the management of obese type 2 diabetic patients traeted with metformin. Diabetes Care 2003; 26(1): 125–31.

2. Acheson KJ, Ravussin E, Wahren J, Jequier E. Thermic effect of glucose in man: obligatory and facultative thermogenesis. J Clin Invest 1984; 74: 1572–80.

3. Aronne LJ, Mackintosh R, Rosenbaum M, et al. Autonomic nervous system activity in weight gain and weight loss. Am J Physiol 1995; 269: R222–5.

4. Astrup A, Bulow J, Christensen NJ, et al. Facultative thermogenesis induced by carbohydrate: a skeletal muscle component mediated by epinephrine. Am J Physiol 1986; 250: E226–9.

5. Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol 1985; 248: E507–15.

6. Berchtold P, Sims EAH, Horton ES, Berger M. Obesity and hypertension: epidemiology, mechanisms, treatment. Biomed Pharmacother 1983; 37: 251–8.

7. Berglund A, Andersson OK, Berglund G, Fagerberg B. Antihypertensive effect of diet compared with drug treatment in obese men with mild hypertension. BMJ 1989; 299: 480–5.

8. Blaak EE, Saris WHM, van Baak MA. Adrenoceptor subtypes mediating catecholamine-induced thermogenesis in man. Int J Obes 1993; 17(Suppl 3): S78–81.

9. Blaak EE, van Baak MA, Kempen KPG, Saris WHM. Role of - and Я-adrenoceptors in sympathetically mediated thermogenesis. Am J Physiol 1993; 264: E11–7.

10. Black HR. Nonpharmacologic therapy for hypertension. Am J Med 1979; 66: 837–42.

11. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995; 3 (Suppl 2): 211S-6.

12. Brand MB, Mulrow CD, Chiquette E, et al. Weight-reduction through dieting for control of hypertension in adults. Cochrane Database of Systematic Reviews 1998; Issue 4.

13. Campese VM, Romoff MS, Levitan D, et al. Abnormal relationship between sodium intake and sympathetic nervous system activity in salt-sensitive patients with essential hypertension. Kidney Int 1982; 21: 371–8.

14. Dahl LK, Silver L, Christie RW. The role of salt in the fall of blood pressure accompanying reduction in obesity. N Engl J Med 1958; 258: 1186–92.

15. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293: 43–53.

16. Ditschuneit HH, Frier HI, Flechtner-Mors M. Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects. Eur J Clin Nutr 2002; 56: 264–70.

17. Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. J Public Health Med 1998; 20: 441–8.

18. Elmer PJ, Grimm R Jr, Laing B, et al: Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prevent Med 1995; 24: 378–88.

19. Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin–angiotensin–aldosterone system. Hypertension 2005; 45: 356–62.

20. Fagerberg B, Andersson OK, Isaksson B, Bjorntorp P. Blood pressure control during weight reduction in obese hypertensive men: separate effects of sodium and energy restriction. Br Med J [Clin Res] 1984; 288: ll-4.

21. Buclin S, Ybarra J, Toti F, et al. New interdisciplinary cognitive-behavioural-nutritional approach to obesity treatment: a 5-year follow-up study.Eating Weight Disord 2004; 9: 24–8.

22. Grassi G, Seravalle G, Colombo M, et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037– 42.

23. Han TS, Williams K, Sattar N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002; 10: 923–31.

24. Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Intern J obesity 1999; 23(10): 1016–24.

25. Hauner H, Meier M, Wendlad G, et al. for the S.A.T. Study Group. Weight reduction by sibutramine in obese subjects in prymarry care medicine: the S.A.T. Study. Exp Clin Endocrinol Diabetes 2004; 112: 201–7.

26. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119.

27. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 2005;7(Suppl L): L44–8.

28. Jeffery RW, Folsom AR, Leupker RV, et al. Prevalance of over weight and weight loss behavior in a metropolitan adult population: the Minnesota Heart Survey experience. Am J Public Health 1984; 74: 349–52.

29. Julius S, Jamerson K, Mejia A, et al. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA 1990; 264: 354–8.

30. Julius S, Krause L, Schork N, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 1991; 9: 77–84.

31. Kaplan N. Non drug treatment of hypertension. Ann Int Med 1985; 102: 359–73.

32. Sjostrom L, Peltonem M, Sjostrom CD. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001; 9(3): 188–95.

33. Landsberg L, Saville ME, Young JB. Sympathoadrenal system and regulation of thermogenesis. Am J Physiol 1984; 247: E181–9.

34. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986; 61: 1081–90.

35. Lasser VI, Raczynski JM, Stevens VJ, et al: Trials of hypertension prevention, phase II: structure and content of the weight loss and dietary sodium reduction interventions: Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 156–64.

36. Liu Y-L, Toubro S, Astrup A, Stock MJ. Contribution of Я3-adrenoceptor activation to epinephrine-induced thermogenesis in humans. Int J Obes 1995; 19: 678–85.

37. Macdonald IA, Bennett T, Fellows IW. Catecholamines and the control of metabolism in man. Clin Sci 1985; 68: 613–9.

38. MacMahon S, Cutler J, Brittain E, Higgins M. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987; 8(Suppl B): 57–70.

39. MacMahon SW, Blacket RB, MacDonald GJ, Hall W. Obesity, alcohol consumption and blood pressure in Australian men and women: the National Heart Foundation of Australia Risk Factor Preva lence Study. J Hypertension 1984; 2: 85–91.

40. MacMahon SW, MacDonald GJ, Bernstein L, et al. Comparison of weight reduction with metoprolol in treatment of young overweight patients. Lancet 1985; 1: 1233–6.

41. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebocontrolled, multicenter trial. Arch Intern Med 2000; 160: 2185–91.

42. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 2000; 8: 270–8.

43. Nangaku M, Izuhara Y, Usuda N, et al. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. Nephrol Dial Transplant 2005; 20: 2661–9.

44. Narkiewicz K, Somers VK, Mos L, et al. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertens 1999; 17: 245–9.

45. O’Dea K, Esler M, Leonard P, et al. Noradrenaline turnoverduring under- and over-eating in normal weight subjects. Metab Clin Exp 1982; 31: 896–9.

46. Palatini P, Vriz O, Nesbitt S, et al. Parental hyperdynamic circulation predicts insulin resistance in offspring: the Tecumseh Offspring Study. Hypertension 1999; 33: 769–74.

47. Paolisso G, Manzella D, Ferrara N, et al. Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Am J Physiol 1997; 273: E471–8.

48. Poehlman ET, Gardner AW, Goran MI, et al. Sympathetic nervous system activity, body fatness, and body fat distribution in younger and older males. J Appl Physiol 1995; 78: 802–6.

49. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulinresistance and the sympatho- adrenal system. N Engl J Med 1996; 334: 374–81.

50. Reisin E, Abel R, Modan M, et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298: l-6.

51. Reisin E, Frohlich ED, Messerli FH, et al. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med 1983; 98: 315–9.

52. Rosenbaum M, Leibel RJ, Hirsch J. Obesity. N Engl J Med 1997; 337: 396–407. (Correction 1998; 338: 555.).

53. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after2 years treatment with orlistat for obesity. Obes Res 8; 2000: 49–61.

54. Scherrer U, Randin D, Tappy L, et al. Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994; 89: 2634–40.

55. Schwartz RS, Jaeger LF, Silberstein S, Veith RC. Sympathetic nervous system activity and the thermic effect of feeding in man. Int J Obes 1987; 11: 141–9.

56. Shechter M, Beigel R, Freimark D, et al. Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. Am J Cardiol 2006; 97: 1650–3.

57. Simonsen L, Bulow J, Madsen J, Christensen NJ. Thermogenic response to epinephrine in the forearm and abdominal subcutaneous adipose tissue. Am J Physiol 1992; 263: E850–5.

58. Simonsen L, Stallknecht B, Bulow J. Contribution of skeletal muscle and adipose tissue to adrenaline-induced thermogenesis in man. Int J Obes 1993; 17(Suppl 3): S47– 51.

59. Sibutramin Clinical Summary Nov 2000-Abbot/Knoll data on file.

60. Staessen J, Fagard R, Amery A. The relationship between body weight and blood pressure. J Hum Hypertens 1988; 2: 207–17.

61. Stevens VJ, Obarzanek E, Cook NR, et al. Long–term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med 2001; 134: 1–11.

62. The Trials of Hypertension Prevention CollaborativeResearch Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. Arch Int Med 1997; 157: 657–67.

63. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92(3): 347–55.

64. Wadden TA, Berkowitz RI, Womble LG, et al. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111–20.

65. Wassertheil-Smoller S, Blaufox D, Oberman AS, et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Int Med 1992; 152: 131–6.

66. Welle S, Schwartz RG, Statt M. Reduced metabolic rate during Я-adrenergic blockade in humans. Metabolism 1991; 40: 619–22.

67. Wheeldon NM, McDevitt DG, Lipworth BJ. Do Я3-adrenoceptors mediate metabolic responses to isoprenaline? Q J Med 1993; 86: 595–600.

68. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled Trial of Nonpharmacologic Inteventions in the Elderly (TONE). JAMA 1998; 279: 839–46.

69. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical. JAMA 1997; 277: 1624–32.

70. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104.

71. Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749–53.

72. Wing RR, Jeffery RW. Outpatient treatments of obesity: a comparison of methodology and clinical results. Int J Obesity 1979; 3: 261–79.

73. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331.

74. Young JB, Landsberg L. Stimulation of the sympathetic nervous system during sucrose feeding. Nature 1977; 269: 615–7.

75. Young JB, Landsberg L. Suppression of sympathetic nervous system during fasting. Science 1977; 196: 1473–5.

76. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144(3): 508–15.

77. Zavoral JH Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16: 2013–7.

78. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804–9.

79. Zurlo F, Larson K, Bogardus C, Revussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 1990; 86: 1423–7.

80. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56(2): 320–8.

81. Sjцsrtцm L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351(26): 2683–93.


Для цитирования:


Недогода С.В., Барыкина И.Н., Брель У.А., Бутрина Л.В., Чаляби Т.А. Ожирение и артериальная гипертензия. Часть I: снижение веса и нормализация артериального давления. Кардиоваскулярная терапия и профилактика. 2008;7(5):105-115.

For citation:


Nedogoda S.V., Barykina I.N., Brel U.A., Butrina L.V., Chalyabi T.A. Obesity and arterial hypertension. Part I: weight reduction and blood pressure normalisation. Cardiovascular Therapy and Prevention. 2008;7(5):105-115. (In Russ.)

Просмотров: 41


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)